close
Add to watchlist
Poniard Pharmaceuticals Inc (PARD)
Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006. Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 2.13 |
| Volume | 0 |
| Volume Avg | 15295 |
| 52 Week High | 30.00 |
| 52 Week Low | 1.91 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -12.26 |
| EPS change Q/Q | -45.45% |
| EPS change Q/Q Yr ago | -79.31% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -177.27% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |